IRIS
CONSOLARO, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 15.858
AS - Asia 1.870
NA - Nord America 1.265
SA - Sud America 133
AF - Africa 41
OC - Oceania 1
Totale 19.168
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 15.565
US - Stati Uniti d'America 1.190
SG - Singapore 803
CN - Cina 439
VN - Vietnam 264
BD - Bangladesh 173
FR - Francia 131
BR - Brasile 76
HK - Hong Kong 60
CA - Canada 40
DE - Germania 31
GB - Regno Unito 24
AR - Argentina 23
IN - India 22
FI - Finlandia 19
JP - Giappone 18
MX - Messico 17
IQ - Iraq 14
NL - Olanda 14
ID - Indonesia 12
EC - Ecuador 10
RU - Federazione Russa 10
TR - Turchia 9
MA - Marocco 8
SE - Svezia 8
CH - Svizzera 7
CO - Colombia 7
ES - Italia 7
IE - Irlanda 7
KE - Kenya 7
PK - Pakistan 7
VE - Venezuela 7
ZA - Sudafrica 7
PH - Filippine 6
SA - Arabia Saudita 6
DZ - Algeria 5
EG - Egitto 5
TN - Tunisia 5
AT - Austria 4
JM - Giamaica 4
PL - Polonia 4
PY - Paraguay 4
TH - Thailandia 4
UA - Ucraina 4
BO - Bolivia 3
CL - Cile 3
DO - Repubblica Dominicana 3
JO - Giordania 3
LB - Libano 3
PR - Porto Rico 3
RO - Romania 3
RS - Serbia 3
AL - Albania 2
AM - Armenia 2
AZ - Azerbaigian 2
BE - Belgio 2
BY - Bielorussia 2
CZ - Repubblica Ceca 2
KZ - Kazakistan 2
MY - Malesia 2
NP - Nepal 2
OM - Oman 2
PT - Portogallo 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
AU - Australia 1
BB - Barbados 1
BZ - Belize 1
CR - Costa Rica 1
CY - Cipro 1
GE - Georgia 1
GR - Grecia 1
HN - Honduras 1
HU - Ungheria 1
IR - Iran 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
LU - Lussemburgo 1
MD - Moldavia 1
MM - Myanmar 1
MN - Mongolia 1
NO - Norvegia 1
PA - Panama 1
SI - Slovenia 1
SN - Senegal 1
SV - El Salvador 1
TG - Togo 1
TZ - Tanzania 1
Totale 19.168
Salva come PNG Salva come JPEG
Città #
Genova 8.887
Genoa 3.804
Rapallo 1.366
Vado Ligure 1.299
Singapore 390
San Jose 338
Ashburn 134
Council Bluffs 129
Lauterbourg 115
Beijing 85
Ho Chi Minh City 80
New York 79
Hanoi 65
Hong Kong 58
Bordighera 31
Santa Clara 31
Los Angeles 26
Frankfurt am Main 25
Boardman 17
Buffalo 17
Tokyo 17
Haiphong 16
Chicago 14
Orem 14
Naples 13
Milan 12
Toronto 12
Da Nang 11
Mexico City 11
Helsinki 10
Montreal 10
Amsterdam 8
Chennai 8
Lappeenranta 8
Cardiff 7
Dallas 7
Rome 7
Shanghai 7
Alessandria 6
City of London 6
Denver 6
Montoro 6
Paris 6
Phoenix 6
Piscataway 6
Tianjin 6
Biên Hòa 5
Bologna 5
Charlotte 5
Dublin 5
Hải Dương 5
Palermo 5
Seattle 5
Zurich 5
Acalanes Ridge 4
Baghdad 4
Kyiv 4
La Spezia 4
Nairobi 4
Rio de Janeiro 4
Warsaw 4
Agadir 3
Amman 3
Atlanta 3
Belgrade 3
Brooklyn 3
Cairo 3
Calgary 3
Cape Town 3
Caracas 3
Cincinnati 3
Des Moines 3
Erbil 3
Esmeraldas 3
Guangzhou 3
Guayaquil 3
Islamabad 3
L’Aquila 3
Manaus 3
Manchester 3
Miami 3
Nuremberg 3
Pittsburgh 3
Porto Alegre 3
Salem 3
San Francisco 3
San Giuseppe Vesuviano 3
Stockholm 3
São Paulo 3
Thái Bình 3
Tunis 3
Washington 3
Adana 2
Athens 2
Avellaneda 2
Barcelona 2
Bari 2
Baton Rouge 2
Benito Juarez 2
Bogotá 2
Totale 17.393
Salva come PNG Salva come JPEG
Nome #
Juvenile Idiopathic Arthritis: Diagnosis and Treatment 218
A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis 213
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score 203
The Slovene version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 203
MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis. 200
Parent and child acceptable symptom state in juvenile idiopathic arthritis. 198
Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology 198
Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis 194
The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 193
Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial 184
The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 184
Development and validation of a composite disease activity score for juvenile idiopathic arthritis 183
Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis 183
IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis 182
The Slovak version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 178
Clinical outcome measures in juvenile idiopathic arthritis 176
A New Approach to Clinical Care of Juvenile Idiopathic Arthritis: The Juvenile Arthritis Multidimensional Assessment Report 175
Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016 175
Advances in biomarkers for paediatric rheumatic diseases 174
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept 173
Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases 171
Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care 169
Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis 168
Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis 163
A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis 163
Evaluation of 21-Numbered Circle and 10-Centimeter Horizontal Line Visual Analog Scales for Physician and Parent Subjective Ratings in Juvenile Idiopathic Arthritis 162
Development and initial validation of composite parent and child centered disease assessment indices for juvenile idiopathic arthritis. 162
Disease activity and damage in juvenile idiopathic arthritis: Methotrexate era versus biologic era 161
A child with a novel ACAN missense variant mimicking a septic arthritis 160
An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis 158
Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study. 158
Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. 156
Recent therapeutic advances in juvenile idiopathic arthritis 156
Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study 156
Filling the Gap: Toward a Disease Activity Tool for Systemic Juvenile Idiopathic Arthritis 154
Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries 153
The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 152
The Algerian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 151
The Bulgarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 150
Development and testing of reduced joint counts in juvenile idiopathic arthritis. 149
Defining criteria for disease activity States in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score. 147
The Canadian English and French versions of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 147
The Chilean Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 147
Predictors of effectiveness of anakinra in systemic juvenile idiopathic arthritis 147
The Swedish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 145
The Colombian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 145
The British English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 144
The Flemish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 144
Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. 143
Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop 143
TCR repertoire sequencing identifies synovial Treg cell clonotypes in the bloodstream during active inflammation in human arthritis 141
The Finnish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 140
The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 140
The Latvian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 140
The Omani Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 139
The Hindi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 138
The Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 138
The Russian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 138
The Afrikaans version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 138
The Serbian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 137
Unraveling the phenotypic variability of juvenile idiopathic arthritis across races or geographic areas - Key to understanding etiology and genetic factors? 136
The Mexican Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 136
The Ecuadorian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 136
The Ukrainian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 135
Delineating the role of multiple intraarticular corticosteroid injections in the management of juvenile idiopathic arthritis in the biologic era. 134
Prevalence of overweight and obesity in 2- to 6-year-old Italian children 134
Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score. 134
The Lithuanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 134
The Castilian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 134
It is worth including assessment of disease activity state in juvenile arthritis clinical trials. 133
The Danish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 133
The Farsi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 133
The Swiss French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 133
The Thai version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 133
The Hebrew version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 132
The Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 132
The Czech version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 132
The Estonian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 132
Female sex and oligoarthritis category are not risk factors for uveitis in Italian children with juvenile idiopathic arthritis. 131
Glucocorticoids in juvenile idiopathic arthritis. 131
The Georgian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 131
Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician's Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI; SDI). 130
The Paraguayan Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 129
Defining criteria for disease activity states in juvenile idiopathic arthritis 128
The Argentinian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 128
Paediatric rheumatology: Juvenile idiopathic arthritis--are biologic agents effective for pain? 127
The Brazilian Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 127
Determinants of discordance between criteria for inactive disease and low disease activity in juvenile idiopathic arhritis 127
Critical role of STIR MRI in early detection of post-streptococcal periostitis with dysproteinaemia (Goldbloom's syndrome) 126
The French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 125
The Norwegian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 125
Ghrelin, insulin sensitivity and postprandial glucose disposal in overweight and obese children 124
The Libyan Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 124
The American English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 123
Information technology in paediatric rheumatology 122
Toward a treat-to-target approach in the management of juvenile idiopathic arthritis. 121
Open issues in the assessment and management of pain in juvenile idiopathic arthritis 119
The Hungarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 119
The Polish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 119
Analysis of arthritis flares after achievement of inactive disease with methotrexate monotherapy in juvenile idiopathic arthritis 119
Totale 14.961
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.024
article - articoli 66.024
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 132.048
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021206 0 0 0 0 0 0 0 0 0 0 0 206
2021/20221.488 72 59 122 119 55 123 61 326 125 175 63 188
2022/20231.632 147 147 21 144 251 274 9 159 276 14 165 25
2023/2024822 35 113 35 110 71 73 89 46 41 35 48 126
2024/20252.973 78 217 111 208 422 365 297 469 75 139 240 352
2025/20264.947 577 161 216 233 667 468 720 217 392 572 491 233
Totale 19.731